Skip to content
The Policy VaultThe Policy Vault

EnbrelMedical Mutual

Graft-Versus-Host Disease (GVHD)

Initial criteria

  • Patient age ≥ 6 years
  • Tried one conventional systemic treatment for GVHD (corticosteroids, antithymocyte globulin, cyclosporine, tacrolimus, mycophenolate)
  • Medication prescribed by or in consultation with oncologist, hematologist, or transplant physician

Reauthorization criteria

  • Patient established on therapy ≥ 1 month
  • Beneficial clinical response (e.g., normalization of labs, resolution of fever/rash) OR symptom improvement (skin, mucosal, ocular, GI)

Approval duration

initial 1 month, reauth 3 months